---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-255127"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:15:51.219301+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Q3 net loss $24.0M; Phase 3 melanoma trial on track for PFS in H1 2025

## Summary
- Net loss $24.0M for Q3 2024 vs $21.7M in Q3 2023; R&D expenses $20.2M up from $17.7M.
- Cash $80.2M as of Sep 30, 2024, down from $143.2M; cash runway into Q4 2025.
- Phase 3 trial IO102-IO103 + pembrolizumab in advanced melanoma: PFS primary endpoint expected H1 2025.
- Phase 2 SCCHN cohort met primary endpoint; data presented at ESMO and SITC.
- Plans BLA submission in 2025 and potential US launch in 2026; IND for IO112 in 2025.

## SEC filing metadata
- accession: 0001193125-24-255127
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312524255127/0001193125-24-255127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312524255127/d793963d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-255127
- JSON: https://secwatch.observer/filing/0001193125-24-255127.json
- Plain text: https://secwatch.observer/filing/0001193125-24-255127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.